Effect of sizofilan, an immunomodulator, on hepatic microsomal mixed-function oxidase activities in rats

Area of Science:

• Pharmacology
• Toxicology
• Biochemistry

Background:

• Mixed-function oxidase (MFO) systems are crucial for xenobiotic metabolism in the liver.
• Cytochrome P-450 enzymes are central to MFO activity and drug detoxification.
• Immunomodulators can potentially influence hepatic metabolic pathways.

Purpose of the Study:

• To investigate the effect of sizofilan (SPG), an immunomodulator, on hepatic MFO activities in rats.
• To determine the impact of repeated SPG administration on cytochrome P-450 content and related enzyme functions.

Main Methods:

• Hepatic microsomal preparations were isolated from rats.
• Rats received intraperitoneal administration of sizofilan (SPG).
• Enzyme activities, including aminopyrine N-demethylase and aniline hydroxylase, and cytochrome P-450 content were measured.

Main Results:

• Repeated doses of sizofilan (SPG) led to a significant depression of hepatic cytochrome P-450 content.
• The activities of aminopyrine N-demethylase and aniline hydroxylase were also depressed following SPG treatment.
• These findings indicate an inhibitory effect of SPG on key MFO enzymes.

Conclusions:

• Sizofilan (SPG) administration negatively impacts hepatic mixed-function oxidase system components in rats.
• The immunomodulator sizofilan (SPG) may alter drug metabolism through inhibition of cytochrome P-450 enzymes.
• Further research is warranted to understand the clinical implications of SPG-induced MFO depression.